Author

Mattia D’Agostino

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoORCID 0000-0002-1711-6996Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1

Frequent Co-Authors

Alessandra LaroccaiD· 2 shared Benedetto BrunoiD· 2 shared Adrienne HellandiD· 1 shared Ahmet A. Kurdoglu· 1 shared Ajai ChariiD· 1 shared Alex Blanski· 1 shared Andrea Donnelly· 1 shared Andrzej J. JakubowiakiD· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alessandra LaroccaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyHaematologicaPeer-reviewedApr 23, 2026

Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma

Michela Cumerlato, Monica Maccagno, María Labrador…·Roberto Piva

This paper identifies bedaquiline as a synergistic agent that enhances proteasome inhibitor efficacy and overcomes resistance in multiple myeloma and related B-cell malignancies.

2 citationstop 4%

humanzebrafish

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintDec 4, 2023

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.

Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino…·Alessandra Larocca

This study identifies genomic and immune factors associated with resistance to anti-CD38 therapy in multiple myeloma patients.

3 citations

humanwhole-genome sequencing

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintAug 2, 2021

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Sheri Skerget, Daniel Peñaherrera, Ajai Chari…·Jonathan J. Keats

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

19 citations

humanwhole-exome sequencing

𝕏 PostBluesky